Results 21 to 30 of about 108,257 (197)

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

Mutations and prognosis in primary myelofibrosis [PDF]

Leukemia, 2013
Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Analysis was performed in 483 European patients and the seminal observations were validated in 396 Mayo Clinic patients.
VANNUCCHI, ALESSANDRO MARIA, Lasho TL, GUGLIELMELLI, PAOLA, BIAMONTE, FLAVIA, Pardanani A, Pereira A, Finke C, Score J, Gangat N, MANNARELLI, CARMELA, Ketterling RP, ROTUNNO, GIADA, Knudson RA, Susini MC, Laborde RR, SPOLVERINI, AMBRA, PANCRAZZI, ALESSANDRO, PIERI, LISA, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A.   +31 more
openaire   +3 more sources

Myelofibrosis and Pancytopenia Associated With Primary Hyperparathyroidism [PDF]

AACE Clinical Case Reports, 2021
OBJECTIVE: Primary hyperparathyroidism (PHPT) has varied clinical presentations. Hematologic abnormalities secondary to PHPT have been described before. However, pancytopenia as the initial presentation has rarely been reported. We report a patient with PHPT who presented for evaluation of pancytopenia.
Rajan, R, Paul, I, Cherian, KE, Korula, A, Hephzibah, J, Manipadam, MT, Abraham, DT, Kapoor, N, Paul, TV   +8 more
openaire   +4 more sources

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

Haematologica, 2015
Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen.
Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès   +16 more
doaj   +1 more source

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos, Juliana Corrêa da Costa Ribeiro, Neusa Pereira Silva, Janete Cerutti, Maria Regina Regis da Silva, Maria de Lourdes Lopes Ferrari Chauffaille   +5 more
doaj   +1 more source

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

Haematologica, 2012
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, Hans Kreipe   +5 more
doaj   +1 more source

Refractory gout in primary myelofibrosis [PDF]

Blood, 2019
![Figure][1] A 66-year-old man from the Dominican Republic presented to the Myeloproliferative Neoplasms Clinic at Mount Sinai with a 10-year history of untreated JAK2V617F- positive primary myelofibrosis (PMF).
Sangeetha Venugopal, John Mascarenhas
openaire   +3 more sources

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]

Journal of Clinical and Diagnostic Research, 2018
Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar, Shaloo Shaloo, Juhi Chawla, Subha Ashok, Shalini Thapar Laroia   +4 more
doaj   +1 more source

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

Frontiers in Oncology, 2022
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara, Cristian Gruppi, Margherita Massa, Maria Enrica Tira, Vittorio Rosti, Alessandra Balduini, Giovanni Barosi   +6 more
doaj   +1 more source